StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultNov 18, 2026, 07:38 AM

Lantern Pharma Q3 Results: $4M Financing, Clinical Updates, CEO Transition

AI Summary

Lantern Pharma Inc. announced its third quarter 2026 financial results and provided several business updates. Key developments include the engagement of the first clinical site for a Phase 1b/2 trial in triple-negative breast cancer, the opening of Part 2 of the HARMONIC™ trial in Taiwan and the U.S. for LP-300, and the peer-reviewed publication of LP-184 Phase 1a glioblastoma data. The company also closed a $4.0 million registered direct offering and announced a leadership transition with the appointment of David Margrave as Interim CEO. Additionally, Lantern reached an agreement in principle to settle claims with a former consultant for $2.0 million and formed a new subsidiary, Open Medicine AI, to commercialize its AI platform.

Key Highlights

  • Lantern Pharma closed a $4.0 million registered direct offering and concurrent private placement on September 30, 2026.
  • First clinical site engaged for Phase 1b/2 trial of LP-184 in triple-negative breast cancer.
  • Taiwan FDA approved amended HARMONIC™ protocol for Phase 2 trial of LP-300; U.S. central IRB also approved.
  • Peer-reviewed publication of LP-184 Phase 1a glioblastoma data supports planned Phase 1b/2a combination trial.
  • Company reached agreement in principle to settle claims with a former consultant for $2.0 million.
  • R&D expenses decreased 36% year over year to $1.6 million for Q3 2026.
  • David Margrave appointed Interim Chief Executive Officer following Panna Sharma's resignation.
  • Formed Open Medicine AI Inc. (OMAI) as a wholly-owned subsidiary to commercialize its AI platform.